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Aims: Enrollment criteria vary substantially among cardiovascular outcome trials (CVOTs) of
sodium-glucose cotransporter-2 inhibitors (SGLT-2is), which impacts the relationship between a
trial population and the general type 2 diabetes (T2D) population. The aim of this study was to
evaluate the representativeness of four SGLT-2i CVOTs of a general T2D population.
Methods: T2D patients from Germany, The Netherlands, Norway and Sweden were included in
the study. Given the available data per country, key inclusion and exclusion criteria were defined
by diagnoses, procedures and drug treatments to facilitate comparability among countries. Rep-
resentativeness was determined by dividing the number of patients fulfilling the key enrolment
criteria of each CVOT (CANVAS, DECLARE-TIMI 58, EMPA-REG OUTCOME, VERTIS-CV) by
the total T2D population.
Results: In 2015, a total T2D population of 803 836 patients was identified in Germany
(n = 239 485), in The Netherlands (n = 36 213), in Norway (n = 149 782) and in Sweden
(n = 378 356). These populations showed a 25% to 44% cardiovascular (CV) disease baseline
prevalence and high CV-preventive drug use (>80%). The general T2D population had less prev-
alent CV disease and patients were slightly older than those included in the CVOTs. The
DECLARE-TIMI 58 trial had the highest representativeness, 59% compared to the general T2D
population, and this representativeness was almost 2-, 3- and 4-fold higher compared to the
CANVAS (34%), EMPA-REG OUTCOME (21%) and VERTIS-CV (17%) trials, respectively.
Conclusions: In large T2D populations within Europe, consistent patterns of representativeness
of CVOTs were found when applying the main enrolment criteria. The DECLARE-TMI 58 trial
had the highest representativeness, indicating that it included and examined patients who are
most representative of the general T2D patients in the studied countries.
KEYWORDS
cardiovascular disease, cardiovascular outcome trial, observational study, representativeness,
SGLT2 inhibitors
1 | INTRODUCTION
Patients with type 2 diabetes are at increased risk of mortality and
cardiovascular (CV) disease.1 Recent cardiovascular outcome trials
(CVOTs) have shown clinically important results in reducing CV risk
when using sodium-glucose cotransporter-2 inhibitors (SGLT-2is), and
further studies are upcoming.2–6 The generalizability of the results of
clinical trials to common clinical practice is recognized as a major
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issue. This is often evaluated as external validity of the study as it is
important in clinical decision making and in implementation of new
clinical guidelines. As enrolment criteria vary among SGLT2-i CVOTs,
it is expected that they will have an impact on the external validity of
the results. An understanding of external validity is particularly impor-
tant as the recently updated ADA/EASD position statement concern-
ing glucose-lowering therapy in patients with T2D has strengthened
the position of SGLT-2is.7 Many CVOTs include patients with a high
risk of CV and with an expected high rate of CV events, to ensure that
differences in CV outcomes may be reported with sufficient statistical
power. As a consequence, various degrees of strict CVOT patient
enrolment criteria may impact the representativeness of the trial pop-
ulation of a general T2D population and, thus, may also impact the
external validity of study results.8,9
Four CVOTs that examined treatment with SGLT-2is are within
the scope of this study.3–6 Major differences exist among these
CVOTs concerning inclusion criteria. Two of the trials included only
patients with established CV disease (EMPA-REG OUTCOME5 and
VERTIS-CV10), while the other two trials also included patients with
additional CV risk factors (DECLARE-TIMI 58,6 ≥ 2 CV risk factors,
and CANVAS,4 ≥ 3 CV risk factors).
The aim of this analysis was to evaluate the representativeness of
four SGLT-2i CVOTs (CANVAS, EMPA-REG OUTCOME, VERTIS-CV,
DECLARE-TIMI 58) by applying the respective main inclusion and exclu-
sion criteria to a general T2D population within four European countries.
2 | MATERIALS AND METHODS
2.1 | Data sources
The present study is part of a large-scale diabetes investigation initia-
tive to acquire an understanding of T2D and its treatment with
drugs.11 The unique features of available health care registries and the
corresponding secondary data from health care systems (claims data
from Germany, electronic health care records data from The Nether-
lands, full population registry data from Norway and Sweden) were
utilized, in order to include all T2D patients who filled prescriptions
for glucose-lowering drugs.11 For a detailed description of data
sources, see Online Supplemental Appendix, Section 1.
2.1.1 | Germany
Data from Germany were obtained from the Betriebskrankenkassen
(BKK), a sickness-fund database consisting of up to 4.9 million insured
individuals who are covered by statutory health insurance (Online
Supplemental Appendix 1.1). The BKK includes routine billing data
from 2007 to 2015 and includes core data concerning the insured
individual and full billing information concerning the hospital health
services utilized, the ambulatory sector and pharmaceuticals. Informa-
tion concerning filled drug prescriptions and hospital visits is updated
on a daily basis and primary care visits are updated on a quarterly
basis. Thus, patients were described on a quarterly basis. Patient data
were fully anonymized before analyses were performed by TeamGe-
sundheit Gesellschaft für Gesundheitsmanagement mbH, Essen, Ger-
many. All required study approvals were obtained.
2.1.2 | The Netherlands
Data for the study were obtained from the PHARMO Database Net-
work in The Netherlands (Online Supplemental Appendix 1.2). This
population-based network of electronic healthcare databases com-
bines and links, through validated algorithms, patient-level data from
different primary and secondary healthcare settings, including data
from general practices, in- and out-patient pharmacies, clinical labora-
tories, hospitals and the cancer, pathology and perinatal registries.
Detailed information on the methodology and the validation of the
record linkage method has been described previously.12,13
2.1.3 | Norway and Sweden
Both Norway and Sweden have comprehensive, nationwide public
health care systems (Online Supplemental Appendix 1.3–S14).14,15 All
citizens have a unique personal identification number (PIN), which is
mandatory for all administrative purposes, including any contact with
the health-care system, as well as drug purchases, thus providing a com-
prehensive medical history of the population. Individual patient-level
data from the Prescribed Drug Registers, the Cause of Death Registers
and the National Patient Registers covering all hospitalizations with dis-
charge diagnoses and all out-patient hospital visits, were linked using
the PIN. The linked databases were separately managed by Statisticon
AB (Uppsala, Sweden).
In Norway (DAPHNE study database), the study protocol was
approved by the Regional Ethics Committee, Helse Sør-st (reference
number 2015/1337/REK sør-øst A) and was authorized by the Norwe-
gian Data Inspectorate (Datatilsynet). In Sweden (DAISY study data-
base), the study protocol was approved by the Stockholm Regional
Ethics Committee (reference number 2013/2206-31), with data linkage
performed by the Swedish National Board of Health andWelfare.
2.2 | Study population
All patients who were using glucose-lowering drugs within the year
prior to 31 December 2015 or during the last quarter of 2015 in Ger-
many, were included (Online Supplemental Appendix 1.2).
2.2.1 | Baseline data
Patient baseline data included characteristics (eg, age and sex), and
comorbidities retrieved from all available data prior to and including the
index date, with the exception of cancer (within 5 years prior to the
index date). Prior medications were defined as any dispensed 12 months
(3 months in the Netherlands) prior to and including the index date.
2.2.2 | Inclusion and exclusion criteria
Adaptation of the inclusion and exclusion criteria of the CVOTs to the
respective countries' health care data was performed by using detailed
diagnostic codes, procedure codes and drug codes (Table S1a–S1d,
Online Supplemental Appendix). Criteria were adapted to the codes
similarly in all countries. The main difference between the included
CVOTs concerns inclusion criteria; the EMPA-REG OUTCOME5 and
VERTIS-CV3 trials included only patients with established CV disease,
while the DECLARE-TIMI 5816 and CANVAS4 trials also included
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patients with CV risk factors only (DECLARE-TIMI 58, ≥2 and CAN-
VAS, ≥3).
2.2.3 | Outcome
Representativeness was determined by dividing the number of
patients fulfilling the four CVOT key inclusion and exclusion criteria
by the total enrolled T2D population.
2.2.4 | Statistical analysis
Demographic data are presented as mean (SD) or n (%). No statistical
comparisons were performed among country results. All analyses
were conducted using SAS, version 9.4 (SAS Institute Inc., Cary, North
Carolina) or R statistical software (R version 3.1.1 or 3.2.3).17
3 | RESULTS
3.1 | Baseline
In total, a T2D population of 803 836 patients was identified in Ger-
many (n = 239 485), in The Netherlands (n = 36 213), in Norway,
(n = 149 782) and in Sweden (n = 378 356) (Table 1). The use of met-
formin was high in all countries (67%–85%). The use of newer oral
glucose-lowering drugs (DPP-4i, SGLT-2i and GLP-1RA) was the
highest in Germany and Norway, whereas use of sulphonylurea was
the highest in The Netherlands and use of insulin was the highest in
Sweden. All four populations had similar CV disease profiles at base-
line, with a prevalence ranging from 25% in Norway to 44% in Ger-
many. The use of CV preventive drug treatment was similarly high,
more than 80%, in all countries.
When comparing the four European T2D populations with the
respective CVOT patients (Table 2), the general T2D patients were
slightly older, were more often women, and had less prevalent CV
disease.
3.2 | Representativeness results
The DECLARE-TIMI 58 trial showed the highest representativeness
(59%), followed by the CANVAS (34%), EMPA-REG OUTCOME (21%)
and VERTIS-CV (17%) trials (Figure 1). Compared to the other CVOTs,
representativeness in the DECLARE-TIMI 58 trial was 2-, 3- and 4-fold,
respectively. Representativeness results were consistent across all four
countries (Figure 2 and Table S2, Online Supplemental Appendix).
3.3 | Sensitivity analysis
When laboratory data available in the database from The Netherlands
were used additionally as inclusion and exclusion criteria, the
TABLE 1 Baseline description of general type 2 diabetes populations in 2015
Germany The Netherlands Norway Sweden
N = 239 485 N = 36 213 N = 149 782 N = 378 356
Age, years (SD) 67.7 (13.0) 68.6 (11.5) 64.1 (13.4) 67.5 (12.3)
Sex (female) 105 406 (44.0) 16 571 (45.8) 64 207 (42.9) 158 030 (41.8)
First GLD, years (SD) 6.1 (2.8) 5.3 (3.6) 6.7 (3.8) 6.8 (4.0)
CV disease 104 547 (43.7) 12 594 (34.8) 37 547 (25.1) 118 852 (31.4)
Myocardial infarction 28 671 (12.0) 3752 (10.4) 10 647 (7.1) 41 444 (11.0)
Unstable angina 13 312 (5.6) 1428 (3.9) 5391 (3.6) 20 843 (5.5)
Heart failure 64 956 (27.1) 2274 (6.3) 10 063 (6.7) 35 980 (9.5)
Stroke 23 566 (9.8) 3491 (9.6) 7499 (5.0) 33 560 (8.9)
Peripheral artery disease 35 831 (15.0) 3715 (10.3) 11 769 (7.9) 24 338 (6.4)
Chronic kidney disease 30 746 (12.8) 6078 (20.4)a 7915 (5.3) 14 856 (3.9)
Cancerb 42 386 (17.7) 5051 (13.9) 18 903 (12.6) 71 158 (18.8)
Metformin use 160 094 (66.8) 30 831 (85.1) 110 600 (73.8) 294 704 (77.9)
Sulphonylurea use 32 941 (13.8) 15 516 (42.8) 32 832 (21.9) 55 030 (14.5)
DPP-4i use 59 644 (24.9) 2373 (6.6) 20 157 (13.5) 48 365 (12.8)
SGLT-2i use 8708 (3.6) 219 (0.6) 11 572 (7.7%) 14 048 (3.7)
GLP-1RA use 4267 (1.8) 507 (1.4) 10 290 (6.9%) 22 949 (6.1)
Metiglinides use 6783 (2.8) 0 (0) 183 (0.1) 13 836 (3.7)
Thiazolidinediones use 212 (0.1) 273 (0.8) 1513 (1.0) 2944 (0.8)
Insulin use 68 055 (28.4) 9532 (26.3) 34 182 (22.8) 135 027 (35.7)
CV preventive drug use 202 022 (84.4) 31 868 (88.0) 123 222 (82.3) 335 910 (88.8)
Low-dose aspirin use 34 869 (14.6) 8183 (22.6) 56 726 (37.9) 120 218 (31.8)
Statins use 102 527 (42.8) 24 912 (68.8) 87 784 (58.6) 243 862 (64.5)
Antihypertensives use 192 832 (80.5) 26 750 (73.9) 105 220 (70.2) 298 238 (78.8)
Receptor P2Y12 antagonists use 11 861 (5.0) 2,356 (6.5) 6265 (4.2) 21 190 (5.6)
Abbreviations: CV, cardiovascular; DPP-4i, dipeptidyl-peptidase-4 inhibitors; GLP-1RA, glucagon-like peptide-1 receptor agonists; SGLT-2i,
sodium-glucose-cotransporter-2 inhibitors.
a In The Netherlands, chronic kidney disease was defined by both diagnosis and laboratory kidney function.
b Cancer diagnosis within five years prior to index.
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representativeness compared to the general T2D populations was, in
general, lower for all four CVOTs (Figure S1, Online Supplemental
Appendix). The most important reason for the lower representative-
ness was the HbA1c inclusion criteria, explained by missing HbA1c
data or by HbA1c being outside the defined range. The DECLARE-
TIMI 58 trial consistently showed the highest representativeness, but
with higher relative differences compared to the primary analysis
described above.
4 | DISCUSSION
In this observational study, we have investigated how four different
SGLT-2i CVOT populations, defined by applying main inclusion and
exclusion criteria from the respective trials, are representative of
general T2D populations in four European countries, Germany, The
Netherlands, Norway and Sweden. We found that the DECLARE-TIMI
58 trial had the highest representativeness, covering approximately
60% of patients in a general T2D population, and this was almost 2-,
3- and 4-fold higher, respectively, as compared to the CANVAS (34%),
EMPA-REG OUTCOME (21%) and VERTIS-CV (17%) trials.3–6 With
only small variations, findings were consistent across all four coun-
tries. Similar patterns, but with more pronounced differences among
the CVOTs compared to the main findings, were seen when also
including laboratory data in the inclusion and exclusion criteria (avail-
able in The Netherlands only).
The most important differences among designs of the respective
CVOTs are the inclusion criteria determining CV risk at baseline, rele-
vant when using CV outcomes as measures. Here, two of the studies,
DECLARE-TIMI 58 and CANVAS, allowed for inclusion of patients
without established CV disease, but with multiple CV risk factors,
whereas the EMPA-REG OUTCOME and VERTIS-CV studies limited
participants to T2D patients with established CV disease.3–6 Our
results clearly show that the use of less restrictive CV inclusion criteria
enhances representativeness, as in the DECLARE-TIMI 586 and CAN-
VAS4 trials as compared to the EMPA-REG OUTCOME and VERTIS-
CV trials.3,5
Wittbrodt et al. recently reported a comparison of representative-
ness of the CVOTs as compared to a US population when also using
laboratory data to define enrolment criteria.18 Interestingly, despite
large differences in data sources as well as demographics and
methods, striking similarities were found in the comparison of US and
Dutch results when laboratory data were used in a sensitivity analysis
(Figure S1, Online Supplemental Appendix). Compared to the results
of our primary analysis without laboratory data, representativeness
was reduced for all CVOTs and the most important explanation for
this was the HbA1c inclusion limits. Also, the relative difference in
representativeness between the DECLARE-TIMI 58 trial and the other
CVOTs increased substantially when including laboratory data, mainly
HbA1c driven, as found in the study by Wittbrodt et al.,18 with less
restrictive HbA1c inclusion criteria than that of the DECLARE-TIMI
58 trial compared to the other trials (Figure S1, Online Supplemental
Appendix).
In principle, CVOT representativeness can be assessed with or
without access to laboratory data, which are not always sufficiently
present in many health care registries. The level of CV risk at baseline
mainly determines the level of CV outcome in CVOTs and must be
comparable to that in the T2D population to enhance the representa-
tiveness of a CVOT. HbA1c is used for trial-specific reasons, has less
impact on CV outcomes, and affects the representativeness of a
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FIGURE 1 Representativeness of patients in cardiovascular outcome
trials when compared to the general type 2 diabetes population
across four European countries. 1. Wiviott S, et al. NEJM. 2018: DOI:
10.1056/NEJMoa1812389. 2. Neal B, et al. NEJM. 2017;377
(7):644-57. 3. Zinman B, et al. NEJM. 2015;373(22):2117-28.
4. Cannon CP, et al. Am Heart J. 2018;206:11-23
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CVOT. Using laboratory data to assess representativeness requires an
HbA1c reading within a reasonable period before index; many
patients will therefore be lost because they do not fulfill HbA1c inclu-
sion criteria or values for them are missing in the registries. Also, in
the eligibility assessment prior to CVOT inclusion, trial-specific HbA1c
measurements are performed to secure enrolment. Hence, the HbA1c
measurement used to determine representativeness in registries is
requested for reasons other than those for HbA1c measurements
prior to trial enrolment. One might discuss which method, with or
without laboratory data, is the most accurate to determine the repre-
sentativeness of a CVOT of a general T2D population, and the truth is
probably somewhere between the two. However, we have shown
that comparison of representativeness among CVOTs remains robust
and can be accessed via health care registries without laboratory data.
With consistent evidence of the beneficial effects of SGLT-2is on
CV risk and their strengthened position in guidelines, it is of high
importance to understand the actual patient profiles in these CVOTs
and, thereby, how representative of a general T2D population the
included patient populations actually are.2,4–7,14,15,19–21 From the pre-
sent analysis, it is clear that the main inclusion criteria, determining
the baseline CV risk in the respective CVOT, are closely correlated to
how representative of a general T2D population the trials are in com-
parison with each other. Trials that include patients with less CV risk
and, consequently, with higher representativeness, require a larger
number of patients to fulfill sufficient power criteria concerning CV
outcomes. Outcomes of such trials may support a broader implemen-
tation of the study results in a real-world setting with a broad spec-
trum of CV risk levels.
The strength of the present study involves the populations, which
are either representative samples (Germany and The Netherlands) or
full populations (Norway and Sweden). The real-world design provides
high external validity and large populations. In addition, the utilized
registers have full coverage for hospitalizations and filled drug pre-
scriptions with established public or private healthcare systems and
few patients are lost to follow-up. CV diagnoses in the registries from
Norway and Sweden have been reported to have high validity.22–26
This analysis is based on registries and therefore carries some lim-
itations relating to the completeness and quality of the registries. Also,
there may be differences among the registries from the four countries,
and it is not possible to analyse the actual cause of the differences in
representativeness as many different criteria seem to interact. For
example, differences among countries in age and CV disease at base-
line seem to play an important role in explaining the differences in
representativeness.
From our analysis, we can determine only which prescriptions
were filled, which does not guarantee actual ingestion of the drug.
As such, we have no information on medication adherence once it
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Germany The Netherlands Norway Sweden
VERTIS-CV (ertugliflozin)4
49% 73% 58% 65%
30% 39% 34% 35%
22% 13% 19% 21% 17% 7% 15% 18%
FIGURE 2 Representativeness of patients in cardiovascular outcome trials when compared to the general type 2 diabetes population in four
European countries 1. Wiviott S, et al. NEJM. 2018: DOI: 10.1056/NEJMoa1812389. 2. Neal B, et al. NEJM. 2017;377(7):644-57. 3. Zinman B,
et al. NEJM. 2015;373(22):2117-28. 4. Cannon CP, et al. Am Heart J. 2018;206:11-23
972 BIRKELAND ET AL.
information on laboratory measurements, which were available only
in The Netherlands as discussed above. Nevertheless, in light of
our findings, a high representativeness of CVOTs concerning level
of CV risk, may help in applying the study results to a real-world
setting.
In conclusion, consistent patterns of representativeness for four
cardiovascular outcome trials involving large T2D populations from
European countries were found when applying main inclusion and
exclusion criteria. In this study, the DECLARE-TIMI 58 trial repre-
sented two out of three general T2D patients, and the estimated rep-
resentativeness was 2-, 3- and 4-fold higher as compared to the
CANVAS, EMPA-REG OUTCOME and VERTIS-CV trials, respectively.
This indicates that the DECLARE-TIMI 58 trial included and examined
patients who are most representative of the general T2D patient in
the studied countries.
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